← Back to Search

Cholinesterase Inhibitor

Donepezil for Wound Healing

Phase 2
Recruiting
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2-4 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

This trial tests if donepezil, a drug for Alzheimer's, can help heal difficult wounds in diabetic patients by improving blood flow and reducing swelling. Donepezil is already approved in many countries for treating Alzheimer's disease.

Eligible Conditions
  • Wound Healing

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2-4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2-4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in depth wound
Change in diameter of the wound

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Donepezil and Topical Zinc OxideExperimental Treatment2 Interventions
donepezil 5mg daily and topical zinc oxide 20% three times daily
Group II: Placebo and Topical Zinc OxidePlacebo Group2 Interventions
Placebo daily and topical zinc oxide 20% three times daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Donepezil
FDA approved

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
711 Previous Clinical Trials
379,232 Total Patients Enrolled
1 Trials studying Wound Healing
~4 spots leftby Nov 2025